A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 3, 2007, Pages 809-816

  Ko, Andrew H ^a   Quivey, Jeanne M ^b   Venook, Alan P ^a   Bergsland, Emily K ^a   Dito, Elizabeth ^a   Schillinger, Brian ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoradiation; Combined modality therapy; Fixed dose rate gemcitabine; Locally advanced; Pancreatic cancer

Indexed keywords

CHEMOTHERAPY; DOSIMETERS; RADIOTHERAPY; TUMORS;

CHEMORADIATION; COMBINED MODALITY THERAPY; FIXED DOSE RATE GEMCITABINE; PANCREATIC CANCER;

ONCOLOGY;

ANTIEMETIC AGENT; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LORAZEPAM; ONDANSETRON; OXALIPLATIN; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INFECTION; LIVER ABSCESS; LIVER FUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALIFORNIA; CISPLATIN; COMORBIDITY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249283789     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.005     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Ceha H.M., van Tienhoven G., Gouma D.J., et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89 (2000) 2222-2229
3. Rich T.A. Radiation therapy for pancreatic cancer: Eleven year experience at the JCRT. Int J Radiat Oncol Biol Phys 11 (1985) 759-763
4. Ko A.H., Dito E., Schillinger B., et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24 (2006) 379-385
5. The NCCN 2. 2006 pancreatic cancer guideline. The complete library of NCCN clinical practice guidelines in oncology (CD-rom) (2007), NCCN, Jenkintown, PA
6. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
7. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
8. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 3 (1985) 373-378
9. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 24 (2006) 4008
10. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15 (1997) 2403-2413
11. Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proceedings of the American Society of Clinical Oncology. Vol 22. Chicago, IL: 2003; p 250.
12. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
13. Grunewald R., Kantarjian H., Keating M.J., et al. Pharmacologically directed design of the dose rate and schedule of 2‴,2‴-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50 (1990) 6823-6826
14. Abbruzzese J.L., Grunewald R., Weeks E.A., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
15. Tempero M., Plunkett W., Ruiz Van Haperen V., et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
16. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion) versus gemcitabine + oxaliplatin in patients with advanced pancreatic cancer (E6201). Proceedings of the American Society of Clinical Oncology. Vol 24. Atlanta, GA: 2006; p. 180s.
17. Vaishampayan U.N., Ben-Josef E., Philip P.A., et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 53 (2002) 675-679
18. Schneider B.J., Ben-Josef E., McGinn C.J., et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1325-1330
19. Sawada N., Ishikawa T., Sekiguchi F., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5 (1999) 2948-2953
20. Stefanidis D., Grove K.D., Schwesinger W.H., et al. The current role of staging laparoscopy for adenocarcinoma of the pancreas: A review. Ann Oncol 17 (2006) 189-199
21. Jimenez R.E., Warshaw A.L., and Fernandez-Del Castillo C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 7 (2000) 15-20
22. Shoup M., Winston C., Brennan M.F., et al. Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma?. J Gastrointest Surg 8 (2004) 1068-1071
23. Wilkowski R., Thoma M., Duhmke E., et al. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 58 (2004) 768-772
24. Blackstock A.W., Tepper J.E., Niedwiecki D., et al. Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34 (2003) 107-116
25. Safran H., Moore T., Iannitti D., et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 49 (2001) 1275-1279
26. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Proceedings of the American Society of Clinical Oncology. Vol 23. Orlando, FL: 2005; p. 1.
27. Cunningham D., Chau I., Stocken D., et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer (2005), ECCO 13, Paris